Hydrogen Therapy: A Promising Breakthrough in Combating Drug-Induced Nephrotoxicity

Drug-induced nephrotoxicity has emerged as a growing concern in contemporary medicine. Many commonly prescribed medications, such as antibiotics and antitumor drugs, can have detrimental effects on kidney function. Cisplatin, a widely used chemotherapy agent, exemplifies the challenges posed by nephrotoxicity. Despite efforts to mitigate its impact through hydration and diuresis, the incidence of nephrotoxicity remains high, affecting 20-30% of patients. However, recent research has shed light on the potential of hydrogen therapy as a protective strategy against cisplatin-induced nephrotoxicity. This groundbreaking approach shows promise in preserving renal health and improving patient outcomes.

Understanding Cisplatin-induced Nephrotoxicity

Cisplatin, known for its efficacy against various solid tumors, unfortunately, comes with the significant dose-limiting side effect of nephrotoxicity. The drug exhibits a high affinity for SH (sulph-hydryl) groups, which not only includes DNA but also crucial cellular components. Cisplatin's interaction with SH groups leads to the depletion of glutathione (GSH), a key antioxidant in cells. As a result, the cellular antioxidant system weakens, leading to the accumulation of reactive oxygen species (ROS) and its byproducts. Compounding the issue, cisplatin tends to accumulate predominantly in the kidneys as it is primarily excreted through this organ, further contributing to renal damage.

The Protective Potential of Hydrogen Therapy

In a pioneering study, Nakashima-Kamimura et al. demonstrated the protective effect of inhaled hydrogen gas against cisplatin-induced nephrotoxicity. Inhalation of 1% hydrogen gas was found to offer significant protection against the acute oxidative stress induced by cisplatin. For short-term treatments, inhalation of 1% or 2% hydrogen gas may be applicable. Additionally, the study revealed that drinking hydrogen-rich water (HW) also yielded a substantial protective effect. This finding opened avenues for exploring hydrogen-rich water as a therapeutic strategy.

Subsequent research confirmed the beneficial effects of hydrogen-rich water in ameliorating cisplatin-induced nephrotoxicity. Studies utilizing dynamic contrast-enhanced CT and blood oxygenation level-dependent magnetic resonance imaging demonstrated that HW improved renal dysfunction and restored the redox equilibrium in rats. Furthermore, hydrogen-rich water exhibited positive outcomes in countering renal damage caused by cyclosporine A, a drug used in organ transplantation. Activation of the Keap1/Nrf2 signaling pathway was identified as a key mechanism through which HW exerted its protective effects.

Unraveling the Promise of Hydrogen Therapy in Combating Renal Fibrosis

Renal fibrosis, a progressive condition characterized by the accumulation of scar tissue within the kidney, represents a significant challenge in the field of nephropathy. This condition affects a substantial portion of the global population, with half of adults over the age of 70 and approximately 10% of people worldwide grappling with its consequences. Understanding the pathogenesis of renal fibrosis and exploring effective defense measures are crucial steps towards improving the prognosis of kidney diseases. Recent studies have shed light on the potential of hydrogen therapy in mitigating renal fibrosis, offering hope for the development of innovative treatment strategies.

The Role of Hydrogen Therapy in Alleviating Renal Fibrosis

In a groundbreaking study, Xing et al. investigated the therapeutic potential of hydrogen-rich water (HW) in a mouse model of renal fibrosis induced by unilateral ureteral obstruction. The results revealed that HW administration effectively alleviated renal fibrosis caused by the obstruction. Moreover, in cellular models, HW demonstrated the ability to prevent the transformation of HK-2 cells from epithelial to mesenchymal state induced by TGF-β1, a key player in fibrosis development. The study further highlighted the involvement of Sirt1, a protein associated with cellular processes, as a potential target for fibrosis treatment and diagnosis.

Building upon these findings, Chen et al. explored the protective effects of hydrogen-rich saline (HRS) in the prevention of renal injury and the inhibition of renal fibrosis in mice following ischemia-reperfusion (IR) injury. The results indicated that HRS played a significant role in retaining the expression of Klotho, a protein with anti-fibrotic properties, and activating autophagy in the kidney. These mechanisms were found to contribute to the suppression of renal fibrosis. These findings open new avenues for non-invasive treatments targeting renal fibrosis.